Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

OCTP.L (OCTP) Share News

IN BRIEF: Oxford Cannabinoid says it remains bound by Takeover Code

17th May 2024 21:45

Oxford Cannabinoid Technologies Holdings PLC - London-based clinical stage biopharmaceutical company - Further to announcement on May 8, reaffirms that it is consistent with the declarations that it made following cancellation of its listing on the Official List, it continues to be subject to the obligations placed on it by the Takeover Code. However, notes if the amendments to the Code proposed in the Public Consultation Paper 2024/1 of April are adopted, the Code would cease to apply to the company after a period of three years following the implementation of those amendments. Read More

Oxford Cannabinoid shares plummet following delisting request

8th May 2024 14:27

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Wednesday said that it has applied to have its shares cancelled from trading on the London Stock Exchange, following an internal strategic review. Read More

Oxford Cannabinoid teams with iNGENu to test OCT130401 pain treatment

11th Apr 2024 13:18

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC announced on Thursday that its subsidiary, OCT Victoria Pty Ltd, has entered an agreement with iNGENu CRO Pty Lt to conduct a study evaluating the safety of OCT130401. Read More

IN BRIEF: Oxford Cannabinoid completes capital reorganisation

16th Feb 2024 14:36

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Says that its capital reorganisation is now complete. Read More

IN BRIEF: Oxford Cannabinoid shares up on applying to admit new shares

15th Feb 2024 11:54

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Following the raising of GBP646,000 through the issue of 128.0 million new shares at a price of 0.5 pence each, as announced late last month, the company says it makes applications to the UK Financial Conduct Authority and London Stock Exchange to admit these shares to the Main Market in London. Expects the new shares to begin trading on Tuesday next week. Following admission, there will be 1.09 billion total Oxford Cannabinoid shares in issue. Read More

IN BRIEF: Oxford Cannabinoid applies for new shares to be listed

14th Feb 2024 19:55

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Says application has been made to the Financial Conduct Authority and the London Stock Exchange Group PLC for the redenominated ordinary shares resulting from the capital reorganisation to be admitted to the Official List. This follows the approval of a capital reorganisation by shareholders in September 2023. Oxford Cannabinoid expects around 960.4 million shares will be admitted to trading and dealings will commence on the London Stock Exchange February 16. Read More

UK shareholder meetings calendar - next 7 days

12th Feb 2024 14:04

Read More

IN BRIEF: Oxford Cannabinoid agrees GBP565,000 loan notes deal

2nd Feb 2024 15:56

Oxford Cannabinoid Technologies Holdings PLC - Oxford, England-based pharmaceutical company developing prescription cannabinoid medicines - Enters convertible loan note agreement with Cantheon Capital LLC, as well as existing shareholders and directors, for up to GBP565,000. Cantheon, an investor in early- and mid-stage biotechnology companies, will provide GBP450,000. The total proceeds will be used to fund phase I trials of Oxford Cannabinoid's trigeminal neuralgia treatment OCT130401, expected to commence in the second quarter of 2024. Trigeminal neuralgia is a condition which affects a nerve inside the skull and can cause severe pain. Oxford Cannabinoid believes that the trigeminal neuralgia market has a value of around GBP1.8 billion. Read More

Oxford Cannabinoid Technologies down after GBP1.2 million fundraise

30th Jan 2024 11:27

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Tuesday announced narrowing losses and a new government tax credit, as shares fell following a fundraise of GBP1.2 million for its latest programme trials. Read More

UK earnings, trading statements calendar - next 7 days

23rd Jan 2024 14:32

Read More

IN BRIEF: Oxford Cannabinoid stock goes high on Europe patent filing

10th Jan 2024 11:46

Oxford Cannabinoid Technologies Holdings PLC - Oxford-based pharmaceutical company developing prescription cannabinoid medicines - Files European patent application in its own name directed to Programme 2. Application is directed to a composition containing Delta-9-tetrahydrocannabinol or THC, and Cannabidiol or CBD. Patent will give company exclusive rights to use, produce and sell this composition most likely for up to two decades, allowing it to recoup its Research & Development investment and gain a competitive market advantage. Notes however that grant process could take up to five years. Company expects to file multiple other Programme 2 applications this year, followed by an international patent application next year. Read More

IN BRIEF: Kingsley Capital reduces stake in Oxford Cannabinoid

20th Oct 2023 09:37

Oxford Cannabinoid Technologies Holdings PLC - Oxford-based pharmaceutical company developing prescription cannabinoid medicine - Kingsley Capital Partners LLP sells 54.9 million shares in the company, of which 20.5 million were acquired by Neil Mahapatra in his own name. Neil Mahapatra, the managing partner of KCP, controls the exercise of 100% of KCP's voting rights in OCT. Kingsley Capital Partners stake in Oxford Cannabinoid falls to 14.95% from 20.76%. Read More

Oxford Cannabinoid completes Phase 1 study for lead asset OCT461201

10th Oct 2023 11:34

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Tuesday said it has "successfully completed" the dosing of all the cohorts of its Phase 1 study for its lead pharmaceutical asset, OCT461201. Read More

Oxford Cannabinoid issues final dose of lead pharmaceutical asset

25th Sep 2023 10:41

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC on Monday said the final dose of its lead pharmaceutical drug compound, OCT461201, has been successfully administered. Read More

UK shareholder meetings calendar - next 7 days

21st Sep 2023 15:50

Read More

EARNINGS SUMMARY: Gulf Keystone swings to loss; Gulf Marine optimistic

31st Aug 2023 17:40

(Alliance News) - The following is a round-up of earnings of London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

SMALL-CAP WINNERS & LOSERS: PPHE Hotels rises on swing to profit

31st Aug 2023 09:53

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday. Read More

UK earnings, trading statements calendar - next 7 days

24th Aug 2023 15:47

Read More

TRADING UPDATES: Pod Point cuts outlook; CVS Group buys in Australia

27th Jul 2023 18:22

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Oxford Cannabinoid expands into oncology; discovers tumour treatment

17th Jul 2023 10:30

(Alliance News) - Oxford Cannabinoid Technologies Holdings PLC said on Monday that it was formally expanding its research & development strategy into oncology, having discovered a potential cannabinoid-based treatment for tumours. Read More

FTSE 100 Latest
Value8,809.74
Change53.53